GUILDify v2.0: A tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets. Aguirre-Plans J, Piñero J, Sanz F, Furlong LI, Fernandez-Fuentes N, Oliva B, Guney E. Journal of Molecular Biology. 2019. 431(13):2477-2484. Partner involved: IMIM
Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches. Rodrigues D, Souza T, Jennen D, Lemmens L, Kleinjans J, de Kok T. Cancer Treatment Reviews. 2019. 77:57-66. Partners involved: UM, Janssen
Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology. Aguirre-Plans J, Piñero J, Menche J, Sanz F, Furlong L, Schmidt H, Oliva B, Guney E. Pharmaceuticals. 2018. 11(3):61. Partners involved: IMIM, UM
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. Copple I, Den Hollander W, Callegaro G. Archives of Toxicology. 2018. 93:1-15. Partner involved: ULIV
Embracing the dark side: Computational approaches to unveil the functionality of genes lacking biological annotation in drug-induced liver injury. Souza T, Trairatphisan P, Piñero J, Furlong LI, Saez-Rodriguez J, Kleinjans J, Jennen D. Frontiers in Genetics. 2018. 9:527. Partners involved: IMIM, UKA, UM
In Silico models in drug development: where we are. Piñero J, Furlong L, Sanz F. Current Opinion in Pharmacology. 2018. 42:111-121. Partner Involved: IMIM
Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX projects. Pastor M, Quintana J, Sanz F. Frontiers in Pharmacology. 2018. 9:1147. Partners involved: IMIM, UPF
Network, transcriptomic and genomic features differentiate genes relevant for drug response Piñero J, Gonzalez-Perez A, Guney E, Aguirre-Plans J, Sanz F, Oliva B, Furlong L. Frontiers in Genetics. 2018. 9:412. Partner involved: IMIM
Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin on vasoconstriction.
Yin A, Yamada A, Stam W, Van Hasselt J, Van der Graaf P. British Journal Pharmacology. 2018. 175(16):3394-3406. Partner involved: UL
Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. Passini E, Britton O, Lu H, Rohrbacher H, Hermans A, Gallacher D, Greig R, Bueno-Orovio A, Rodriguez B. Frontiers in Physiology. 2017. Partner involved: UOXF |
The work reported in this article has won the 2017 3Rs Prize, awarded by the NC3Rs. More information here